References
- Gibson R, Burns J, Ramsey B. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med.168(8), 918–951 (2003).
- Prince A. Biofilms, antimicrobial resistance, and airway infection. N. Engl. J. Med.347(14), 1110–1111 (2002).
- Marchetti F, Giglio L, Candusso M, Faraguna D, Assael B. Early antibiotic treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur. J. Clin. Pharmacol.60(2), 67–74 (2004).
- Smyth A. Multiresistant pulmonary infection in cystic fibrosis–prevention is better than cure. Lancet366(9484), 433–435 (2005).
- Moskowitz S, Foster J, Emerson J, Burns J. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol.42(5), 1915–1922 (2004).
- Aaron S, Ramotar K, Ferris W et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med.169(7), 811–815 (2004).
- Spencker F, Staber L, Lietz T, Schille R, Rodloff A. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin. Microbiol. Infect.9(5), 370–379 (2003).
- Macia M, Blanquer D, Togores B et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother.49(8), 3382–3386 (2005).
- Blazquez J. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis.37(9), 1201–1209 (2003).
- Scott F, Pitt T. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J. Med. Microbiol.53(Pt 7), 609–615 (2004).
- Al-Aloul M, Crawley J, Winstanley C et al. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax59(4), 334–336 (2004).
- Pfaller M, Jones R. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001–2003). Arch. Pathol. Lab. Med.130(6), 767–778 (2006).
- Burns J, Saiman L, Whittier S et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis.39(4), 257–260 (2001).
- Burns J, Saiman L, Whittier S et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Clin. Microbiol.38(5), 1818–1822 (2000).
- Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect. Control Hosp. Epidemiol.24(Suppl. 5), S6–S52 (2003).
- Zhou J, Garber E, Desai M, Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J. Clin. Microbiol.44(4), 1547–1549 (2006).
- Hassett D, Cuppoletti J, Trapnell B et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv. Drug Deliv. Rev.54(11), 1425–1443 (2002).
- Pitt T, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax58(9), 794–796 (2003).
- Hill D, Rose B, Pajkos A et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol.43(10), 5085–5090 (2005).
- Morosini M, Garcia-Castillo M, Loza E et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range E test strips. J. Clin. Microbiol.43(9), 4480–4485 (2005).
- Jones RN, Anderegg T, Swenson J. Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J. Clin. Microbiol.43(2), 925–927 (2005).
- Saiman L, Mehar F, Niu W et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis.23(3), 532–537 (1996).
- Lang B, Aaron S, Ferris W, Hebert P, MacDonald N. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med.162(6), 2241–2245 (2000).
- Aaron S, Vandemheen K, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet366(9484), 463–471 (2005).
- Smith A, Fiel S, Mayer-Hamblett N, Ramsey B, Burns J. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest123(5), 1495–1502 (2003).
Website
- CF referral center for susceptibility and synergy studies http://synergy.columbia.edu